BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Sees Significant Drop in Short Interest

BriaCell Therapeutics Corp. (NASDAQ:BCTXW) saw a large decline in short interest in the month of February. As of February 13th, there was short interest totaling 11,464 shares, a decline of 25.2% from the January 29th total of 15,325 shares. Based on an average daily volume of 43,263 shares, the short-interest ratio is presently 0.3 days. Based on an average daily volume of 43,263 shares, the short-interest ratio is presently 0.3 days.

BriaCell Therapeutics Stock Performance

BCTXW opened at $0.00 on Monday. BriaCell Therapeutics has a fifty-two week low of $0.00 and a fifty-two week high of $0.25. The firm has a 50-day moving average of $0.02 and a 200 day moving average of $0.03.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on the development of novel immunotherapeutic treatments for breast cancer and other solid tumors. The company’s research strategy centers on harnessing the body’s immune system to recognize and attack cancer cells, with an emphasis on off-the-shelf allogeneic platforms that can be readily administered without the need for patient-specific manufacturing.

The company’s lead candidate, Bria-IMT, is derived from a human breast tumor cell line engineered to express immune-stimulatory molecules designed to trigger both innate and adaptive anti-tumor responses.